Accure Therapeutics launched in May 2020 with a €7.6M ($8.1M) Series A. Alta Life Sciences led the round, with support from CDTI, the Spanish Centre for Technological and Industrial Development. The Barcelona company develops a portfolio of new drug candidates for diseases of the central nervous system (CNS).

About Accure Therapeutics
Accure Therapeutics is a pharma R&D company in the CNS field. It integrated the assets of two Barcelona biotech startups, Bionure and Iproteos, into a single portfolio, as Catalonia.Health reported. A team with long experience in pharma and biotech runs operations.
CNS diseases, including neurodegenerative and neurological conditions, have high unmet medical need and high failure rates in drug development. Combining several programmes in one company spreads risk and makes better use of a specialist team.
The Series A
The round was reported by Capital Riesgo. Alta Life Sciences is a Spanish life sciences investor. CDTI’s participation brought public funding alongside venture capital, which is common in Spanish biotech financing.
Building a company from existing assets
Creating a new company around assets from earlier startups is a model used by venture investors to give promising science a second chance with fresh capital and management. It requires care in several areas:
- Transfer of IP and data from the original companies.
- Treatment of existing public loans and grants attached to the assets.
- Agreements with former shareholders and founders.
- A development plan that prioritises the most promising programmes.
- A finance function set up from day one for investor and funder reporting.
Five lessons for investors in CNS biotech
- Portfolios reduce single-asset risk. Several programmes increase the chance that at least one succeeds.
- Prioritise ruthlessly. Limited capital must go to the programmes with the best data and clearest path.
- Experienced teams matter. Managers who have run CNS programmes before avoid costly mistakes.
- Public co-funding stretches capital. CDTI and other programmes extend runway but need careful reporting.
- Plan partnering early. CNS trials are expensive. Licensing deals with pharma often fund later stages.
What biotech founders should prepare
- Programme budgets with milestones and decision points.
- IP and data transfer documentation.
- A list of public funding and its conditions.
- Accounts reconciled to the statutory filings.
- A partnering strategy and target list.
The CNS opportunity
Ageing populations are increasing the burden of neurodegenerative disease, and treatments for many CNS conditions remain limited. Pharma companies are active buyers of promising CNS assets, but they look for strong early data. A focused company with a portfolio can generate that data efficiently and become a partner for larger groups.
Why Accure Therapeutics chose a combined model
Small biotech companies with a single preclinical programme struggle to raise enough capital to reach clinical data. Each one carries its own overhead: management, finance, legal, office and laboratory. Combining programmes from Bionure and Iproteos into Accure Therapeutics shares those costs and lets one experienced team manage several assets. Investors get exposure to more than one shot at success, and the company can stop weaker programmes without closing down.
For finance, the combined model means tracking costs and results by programme, so that the board can compare them and decide where to invest next. Clear programme accounting also helps when a single asset is later licensed or sold.
Metrix Partners in life sciences
Metrix supports life sciences companies with finance, funding and transactions. Clients include Ona Therapeutics, DeepUll and VB Devices.






